More on AKBA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.21 |
|
|||
| Open | $1.22 | ||||
| 52 Wk High | $13.20 | ||||
| 52 Wk Low | $7.00 | ||||
| Day High | $1.24 | ||||
| Day Low | $1.16 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,198,655 | ||||
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Form 4 Akebia Therapeutics, For: Jun 29 Filed by: Ostrowski Erik
- H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
- Form 8-K Akebia Therapeutics, For: Jun 30
- Vafseo trial stopped early after interim data shows fewer hospitalizations
- U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
- Form 144 Akebia Therapeutics, Filed by: Ostrowski Erik
- Form 4 Akebia Therapeutics, For: Jun 17 Filed by: Wolf Myles
- Form 4 Akebia Therapeutics, For: Jun 17 Filed by: Smith Cynthia
- Form 4 Akebia Therapeutics, For: Jun 17 Filed by: ROGERS MICHAEL W
Entities mentioned with AKBA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- 13G | View Related Stories »
- Needham & Company | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
